Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 16;15(8):1007.
doi: 10.3390/ph15081007.

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Anastasia Stella Perpinia  1 , Nikolaos Kadoglou  2 , Maria Vardaka  3 , Georgios Gkortzolidis  3 , Apostolos Karavidas  1 , Theodoros Marinakis  3 , Chrysostomi Papachrysostomou  1 , Panagiotis Makaronis  1 , Charikleia Vlachou  3 , Marina Mantzourani  4 , Dimitrios Farmakis  2 , Konstantinos Konstantopoulos  5
Affiliations
Review

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

Anastasia Stella Perpinia et al. Pharmaceuticals (Basel). .

Abstract

Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.

Keywords: anthracyclines; anticancer targeted therapies; cardiotoxicity; heart failure; leukemia; lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of Anthracycline-induced cardiotoxicity.
See this image and copyright information in PMC

References

    1. Fitzmaurice C., Akinyemiju T.F., Hasan F., Al Lami F.H., Alam T., Alizadeh-Navaei R., Allen C., Alsharif U., Alvis-Guzman N., Amini E., et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4:1553–1568. doi: 10.1001/jamaoncol.2019.2996. - DOI - PMC - PubMed
    1. Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., Marcos-Gragera R., Maynadié M., Simonetti A., Lutz J.-M., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood. 2010;116:3724–3734. doi: 10.1182/blood-2010-05-282632. - DOI - PubMed
    1. Sant M., Minicozzi D., Mounier M., Anderson L.A., Brenner H., Holleczek B., Marcos-Gragera R.M., Maynadié M., Monnereau A., Osca-Gelis G., et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–942. doi: 10.1016/S1470-2045(14)70282-7. - DOI - PubMed
    1. López-Fernández T., Martín-García A., Beltrán A.S., Luis A.M., Sanz R.G., Ramos P.M., del Castillo S.V., de Sá Areses E.L., Barreiro-Perez M., Baydes R.H., et al. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Rev. Esp. Cardiol. 2017;70:474–486. doi: 10.1016/j.recesp.2016.12.021. - DOI - PubMed
    1. Skitch A., Mital S., Mertens L., Liu P., Kantor P., Grosse-Wortmann L., Manlhiot C., Greenberg M., Nathan P.C. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: A multi-centre observational study. BMC Cancer. 2017;17:519. doi: 10.1186/s12885-017-3505-0. - DOI - PMC - PubMed